Consistently, FACS analysis of tumor tissues at the treatment endpoint showed a significant increase in total CD8+ TILs and a decrease in exhausted CD8+ T cell subpopulations with combination treatment (Fig. 3f). The gene discussed is CD8A; the disease is neoplasm.